Panelists review unmet needs in clostridium difficile infection management and consider how medical policies are evolving to address them.
Transcript:
Neil Minkoff, MD: Let me ask this question. We’ve talked a lot about what’s going on in this space. We’ve talked about some of the different medications, the difficulty of treatment, recurrence, and when to accelerate to a higher level of treatment. I want to open this up to everybody: What’s the biggest unmet need in recurrent Clostridioides difficile infection, whether it’s your coverage policy or your practice? What do you think would be the best thing for us to address?
Jessica Allegretti, MD, MPH: In the big picture, the best thing we could do for patients long term is primary prevention. If we can prevent C diff from even happening, then we don’t have to worry about recurrent C diff. That includes things like vaccines and some of these primary preventive agents. Or when patients are going into the hospital and getting on broad spectrum antibiotics, how can we prevent that subsequent C diff infection? That’s probably the biggest unmet need and the most exciting place to be working to prevent this from happening at all.
That being said, in lieu of that, we need more effective therapies to treat and eradicate recurrent C diff to ultimately result in decolonization and not keep these patients in a vulnerable microbiome space, if you will. I’m very pleased and excited to see all these novel microbiome therapeutics being studied.
We need FDA-approved therapies. I’m a true believer in FMT [fecal microbiota transplantation]. Obviously, I believe in the safety and efficacy of that product. It’s never going to be FDA approved. That’s quite clear to all of us. In lieu of that, we need products that we can use that are effective and safe. From my perspective, that’s what we need right now.
Neil Minkoff, MD: Any others?
Dale N. Gerding, MD: I agree. Primary prevention is where we need to be. There’s 1 vaccine pending; we’ve been waiting a long time for the announcement. One has already failed. But there are other modalities coming that will also be effective in primary prevention if we can establish those methodologies. However, those are still in the research stage.
But in the case of preventing recurrence, we need a safe, effective, and cost-effective way to prevent C diff recurrences that you can use with the first episode. We need to get on top of this as soon as it occurs the first time, because the real need here is to prevent patients from having any recurrences at all. We’re focused on multiple recurrences because they’re devastating to people, both emotionally and physically.
We also need to find the means to develop treatment agents that will prevent recurrence with the first episode. One of the big barriers right now is the cost of these preventive agents. Everything we’ve talked about so far has been more expensive than standard therapies. You’re trying to weigh the benefit of those more expensive therapies against their acquisition cost. We need something that works well, is safe, and doesn’t cost a whole lot.
Neil Minkoff, MD: You just defined the holy trinity.
Kevin U. Stephens, Sr. MD, JD: Absolutely. That’s right on point, because obviously it’s a balancing system, and you have to figure out outcomes vs cost vs patient satisfaction. To answer your question about what we need, we need more studies, research, randomized studies that show the effectiveness and cost-benefit, or CBAs [cost-benefit analyses], as we call it. That can help push us to better decisions, particularly as a payer.
Karina Abdallah, PharmD: I agree. Our unmet needs are FDA approval and new agents. Even if we don’t get Dr Gerding’s full wish list with lower cost, at least proven success. The ability to prove that being proactive will ultimately bring down not only the cost but also improve patient experience. Earlier on, Dr Allegretti took us through what a horrible experience this can be, not only for the patient but for their family. It’s important to bring in that whole picture. Dr Stephens earlier also mentioned behavioral health. Maybe even bringing that under the behavioral health umbrella and connecting it with nursing case management on the payer side. Most payers have a good, strong force of nursing case management. Maybe connecting that with hospital discharges, that can be an unmet need as well that we touched on a little.
It’s about being as proactive as we can and not only looking at the recurrent C diff population. Some quick statistics: before Medicare Advantage, a third of the primary cases end up in recurrence. It’s important to target the primary cases and be as proactive as possible, tracking what their risk factors are and what therapies they’re on. Are they following up with GI [gastrointestinal] or ID [infectious disease] physicians to manage their care all the way through? Connecting any coordination that we can do between the payer, health system, facility, and even at home for the patients is key.
Transcript edited for clarity.
5 Things Everyone Should Know for National Immunization Awareness Month
August 1st 2025National Immunization Awareness Month highlights the importance of lifelong vaccination to prevent diseases, a practice that has averted millions of deaths, proven to be a cost-effective public health strategy, and offers crucial protection even to individuals who are immunocompromised.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
July 31st 2025A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and supporting continued use in high-risk populations amid ongoing viral evolution.
Read More
Bird Flu Risks, Myths, and Prevention Strategies: A Conversation With the NFID's Dr Robert Hopkins
January 21st 2025Joining us for this episode of Managed Care Cast is Robert H. Hopkins Jr, MD, medical director at the National Foundation for Infectious Diseases (NFID), who will help separate fact from fiction about avian influenza and discuss what needs to be done to prevent a future escalation.
Listen
Breaking Down Barriers to Hepatitis Elimination on World Hepatitis Day 2025
July 25th 2025World Hepatitis Day 2025 and its theme, “Hepatitis: Let’s Break It Down,” emphasize the urgent need to remove barriers to prevention, testing, and treatment to reduce liver cancer and eliminate hepatitis by 2030.
Read More